Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Stop drinking this early. Earnings are next week.
Just the fact that McKeeson is endorsing us publicly again, along with mentioning our upcoming workshop with Fisher and GE is fabulous. We're pissin with the big dogs. Now give me a minimum 3.5 million dollar 4th quarter and we are on our way. Fingers crossed.
The link has been at the top of the Cryoport Investors Hub page since this morning
If successful could this effect our number of shipments?
https://investor.sangamo.com/press-releases/detail/397/kite-a-gilead-company-and-sangamo-therapeutics-announce
There wwas an extensive segment today on the Megyn Kelly show today with a woman who went through CAR T cell therapy at MD Anderson. You may be able to pick it up on Ondemand.
AMEN
HUH? A few typo's:
According to Zacks, analysts expect that CryoPort will report full year sales of $3.39 million for the current fiscal year, with estimates ranging from $11.90 million to $12.17 million
The company has an average rating of “Buy” and a consensus target price of $33.50.
Nice info:
https://www.dispatchtribunal.com/2017/12/31/royce-associates-lp-purchases-shares-of-137200-cryoport-inc-cyrx.html
$33.50 at the end of the 3rd paragraph?
You too Bust. Not a bad year from a little over 3 in January to around $9 this year. Looking for a double this year.
Nice rally the past 2 sessions. Hopefully it holds today.
Thank you
And I'm sure you have the scars to prove it! Who was the guy who was always posting about the Falcon? If you can remember way back then.
Since I have owned this stock since the Investors Village board days with posters such as Tigertrader and Bostonman, do I qualify as a long term holder?
Although this article does not mention us by name, it does explain the importance of shipping and handling during the process.
https://www.statnews.com/2017/10/27/car-t-kite-cell-journey/?utm_source=STAT+Newsletters&utm_campaign=14828888c6-Readout&utm_medium=email&utm_term=0_8cab1d7961-14828888c6-130670785
Good news for one of our customers:
http://www.investors.com/news/technology/spark-therapeutics-gains-panel-nod-for-gene-therapy-to-treat-blindness/
I have no problem with Robert.
193,100 share trade at the close.
To me this is the most eye opening statement in your post:
"Despite the vast resources and capabilities of these competitors, all of the leading-edge, top names in the regenerative therapy market; Novartis, Kite, Bluebirdbio, Juno have chosen to partner with Cryoport. As of last year, they were supporting 23 of the 28 CAR-T clinical programs, and as of last quarter were supporting 172 of 899 clinical trials (18%) in regenerative therapy".
To be getting commitments from major companies is a huge accomplishment for a little "pip squeak" outfit like CYRX. If we are able to get only 3% of the market by 2021 we will be close to a 50 million dollar a year company. I feel 3% is easily achievable given our current and future alliances and market share could go much higher.
I was not aware of the aquisition of Marken late last year so I guess our relationsip with UPS is less than ideal from this point forward.
Here is a little info. I found on the internet regarding the latest acquisition
Feb. 1.17 | About: United Parcel (UPS) by Charles Fournier
Marken Acquisition (completed December 2016)
UPS completed its acquisition of Marken on December 22, 2016. The acquisition of Marken follows multiple UPS acquisitions that have expanded the company's healthcare logistics services portfolio.
Marken is the only patient-centric supply chain organization 100% dedicated to the pharmaceutical and life sciences industries. It maintains the leading position for Direct to Patient services and biological sample shipments and offers a state-of-the-art Good Manufacturing Practices (GMP) compliant depot network and logistic hubs.
GMP, by the way, is a system for ensuring that products are consistently produced, controlled, and delivered according to quality standards. It is designed to minimize the risks involved in any pharmaceutical production that cannot be eliminated through testing the final product.
Marken has almost 700 staff members in 45 locations worldwide, including 10 depots that are compliant with GMP. It manages 50,000 drug and biological shipments every month at all temperature ranges to more than 150 countries. Additional services include biological kit production, ancillary material sourcing, storage and distribution, and shipment lane qualifications.
Pharmaceutical companies, clinical research organizations, and contract manufacturers rely on Marken for collection and transportation of clinical trial material and investigational medicinal products. In addition, they rely on Marken for the shipment of biological samples from these sites to central laboratories. These shipments are time- and temperature-sensitive, and their rapid, on-spec delivery is a key factor in the treatment of patients and the success of the clinical trial.
Yea, I really went out on a limb when it was already 9.99.
I think we could hit 10 today.
Screw your tight pants! At $40 I will buy you a new wardrobe.
I am also a long time investor having bought some of my shares in April,2007. Since that time I have suffered a 1:10 split in 2010 and a 1:12 split in 2015. Fortunately I am now in the black(barely) but I am not interested in buyout talk or selling until we are at least in the $25-30 plus dollar range. I feel the desire for a buyout is shortsighted given the future of the industry as well as our product. I do not want to give GE or anybody else the profits I have waited for since April, 2007. I can see $20-$25 by the end of 2018.
I was never aware of Emily Whitehead:
http://www.nejm.org/doi/full/10.1056/NEJMp1711886
Do we know which of the products require our dewars?
https://finance.yahoo.com/news/cryoport-selected-support-potential-commercial-123000319.html
I like this part:
In 2016, Cryoport and Kite expanded the agreement between the companies to support Kite's trials for its clinical stage therapies. Today, Cryoport provides cryogenic logistics support for six additional clinical stage therapies by Kite Pharma.
On an industrywide basis, Cryoport currently supports over 140 clinical trials for its biopharma clients, 17 of which are in Phase III.
I don't believe the float is that much less than the outstanding shares right now.
This article lists some of the big boys that are investing in CYRX:
https://www.dispatchtribunal.com/2017/08/31/cryoport-inc-cyrx-trading-12-1-higher-following-analyst-upgrade.html
This could get very interesting. Gilead does 30 billion a year in business and has joint venture deals with BMS which is already a customer of CYRX. This could open the door to our biggest client to date.
I don't like this one either. A Director with no investment in the company.
Cryoport, Inc. director just disposed of 21,396 shares
Richard J Berman, a director of Cryoport, Inc., recently disposed of 21,396 shares of the company. The disposals took place at prices ranging from $7.65 to $7.80 per share, on dates ranging from August 14 to August 15, 2017. Berman no longer owns any shares of the company. Berman operates out of Irvine, CA.
I do not see this as positive news:
https://www.usatoday.com/story/news/2017/08/22/breakthrough-cancer-drug-astronomical-price/589442001/
Interesting reads:
http://www.reuters.com/article/us-novartis-malaria-idUSKCN1B10KN?feedType=RSS&feedName=healthNews&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+reuters%2FhealthNews+%28Reuters+Health+News%29
https://endpts.com/preemptive-shaming-assault-on-novartis-car-t-pioneer-underscores-a-disconnect-on-rd-costs/?utm_medium=email&utm_campaign=Monday%20August%2021%202017&utm_content=Monday%20August%2021%202017+CID_2311273bf06e97b209e3cdc0fc98ba02&utm_source=ENDPOINTS%20emails&utm_term=Preemptive%20shaming%20assault%20on%20Novartis%20CAR-T%20pioneer%20underscores%20a%20disconnect%20on%20RD%20costs
2.9 million in revenue for the quarter